Literature DB >> 12084274

Complexed prostate-specific antigen improvement in detecting prostate cancer.

K Okihara1, R J Babaian.   

Abstract

This article presents the current reports of complexed prostate-specific antigen (PSA) aimed for the enhancement of prostate cancer detection. Further studies are needed to ascertain the variability of complexed PSA. Comparisons of percent free PSA, potential additive value of alpha(1)-antichymotripsin-bound PSA (PSA-ACT) and Bayer complexed PSA (cPSA) remains controversial in men with intermediate elevated total PSA concentration. Volume-referenced complexed PSA (PSA-ACT and cPSA) can enhance prostate cancer detection. Preliminary results show that PSA-alpha(2)-macrobloblin (PSA-a(2)M) and PSA-alpha(1)-protease inhibitor (PSA-API) are promising assays for improving cancer detection.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 12084274     DOI： 10.1007/s11934-001-0088-7

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  38 in total

1.  Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia .

Authors:  X Filella; J Alcover; R Molina; J M Corral; P Carretero; A M Ballesta
Journal:  Prostate       Date:  2000-02-15       Impact factor: 4.104

2.  Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin.

Authors:  W M Zhang; P Finne; J Leinonen; S Vesalainen; S Nordling; S Rannikko; U H Stenman
Journal:  Clin Chem       Date:  1998-12       Impact factor: 8.327

3.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

4.  Advantages of replacing the total PSA assay with the assay for PSA-alpha 1-antichymotrypsin complex for the screening and management of prostate cancer.

Authors:  J T Wu; G H Liu
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

5.  Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma.

Authors:  E Kikuchi; J Nakashima; M Ishibashi; T Ohigashi; H Asakura; M Tachibana; M Murai
Journal:  Cancer       Date:  2000-08-15       Impact factor: 6.860

6.  Prostatic manipulation has a minimal effect on complexed prostate-specific antigen levels.

Authors:  N N Lynn; G N Collins; P H O'Reilly
Journal:  BJU Int       Date:  2000-07       Impact factor: 5.588

7.  Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.

Authors:  T Björk; T Piironen; K Pettersson; T Lövgren; U H Stenman; J E Oesterling; P A Abrahamsson; H Lilja
Journal:  Urology       Date:  1996-12       Impact factor: 2.649

8.  Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume.

Authors:  T A Stamey; C E Yemoto
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

Review 9.  Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate.

Authors:  H G Rittenhouse; J A Finlay; S D Mikolajczyk; A W Partin
Journal:  Crit Rev Clin Lab Sci       Date:  1998-08       Impact factor: 6.250

10.  Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers.

Authors:  A F Prestigiacomo; T A Stamey
Journal:  J Urol       Date:  1996-06       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.